A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Eli Lilly and Company

Summary

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * refer to the GZPL master protocol for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol for screening eligibility.

Interventions

Drug
Orforglipron
Administered orally
Drug
Placebo
placebo administered.

Locations (99)

Elite Clinical Studies, LLC
Phoenix, Arizona
Valley Clinical Trials, Inc.
Covina, California
Valley Clinical Trials, Inc.
Northridge, California
Chase Medical Research, LLC
Waterbury, Connecticut
Excel Medical Clinical Trials
Boca Raton, Florida
Care Access - Brandon
Brandon, Florida